

Attorney Docket No. 46963-DIV (71417)

U.S.S.N. 09/228,020

Filing date: January 11, 1999

Supplemental Amendment and Remarks

3 of 4

27 to correct an inadvertent typographical error. The amendments do not introduce new matter and support for the amendments may be found in the specification and claims as originally filed.

### CONCLUSION

Applicants submit that all claims are allowable as written and respectfully requests early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicants' agent would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned agent of record.

Respectfully submitted,

Date: December 5, 2002

By: Dianne Rees  
Dianne Rees, Ph.D.  
Reg. No. 45,281  
EDWARDS & ANGELL, LLP  
PO BOX 9169  
Boston, MA 02209

Telephone: 1-617-951-3351

Fax: 1-617-439-4170

Customer No: 21,874

Attorney Docket No. 46963-DIV (71417)  
U.S.S.N. 09/228,020  
Filing date: January 11, 1999  
Supplemental Amendment and Remarks  
4 of 4

### **Marked-Up Version of Specification Showing Changes Made**

At page 47, the abstract is amended as follows:

[In accordance with the present invention,] Pharmaceutical products are provided comprising EC progenitors [can be used in a method] for use in methods for regulating angiogenesis, i.e., for enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting an angiogenesis modulator to specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g., anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.

### **Marked-Up Version of Claim Showing Changes Made**

Claim 27 is amended as follows.

27. (Amended) The pharmaceutical product of claim 26, wherein the vector comprises human immunodeficiency virus (HIV) gag and pol genes.

10082.J20433.1